Frequency completes enrollment in safety trial for hearing loss drug

Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate.

The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in the inner ear.

Get the full story at our sister site, Drug Delivery Business News.

The post Frequency completes enrollment in safety trial for hearing loss drug appeared first on MassDevice.

from MassDevice https://ift.tt/2IHpUVm